Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

Gil Candel, Mayte; Gascón Cánovas, Juan José; Urbieta Sanz, Elena; Gómez Espín, Rosa; Nicolás de Prado, Isabel; Iniesta Navalón, Carles.
Rev. esp. enferm. dig ; 112(5): 360-366, mayo 2020. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-195589

Documentos relacionados

  1. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
  2. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
  3. Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?
  4. Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
  5. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
  6. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients.
  7. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
  8. Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.
  9. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
  10. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.